Intramuscular injections should be avoided because injections are painful and inconvenient, and absorption is erratic. Thrombocytopenic patients are a risk for hematomas at the injection site and neutropenic patients or individuals on chronic steroid therapy are at increased risk for site infection and systemic infection. If this route is used, a concentrated opioid should be given to keep the volume of injection as small as possible. This is the most concentrated commercially available injectable opioid. This preparation may also be administered subcutaneously.
Administration can be by intermittent bolus injections or continuous infusion with bolus dosing.
Secondly, the duration of action is longer than with any other route of administration. Proper patient selection and consideration of long term maintenance are critical. Website Copyright 1999-2001, Texas Cancer Council . All Rights Reserved. Site last updated September 18, 2001.